GeneDx has appointed Everett Cunningham as its next chief executive officer, succeeding Katherine Stueland after her five-and-a-half-year tenure. The GeneDx CEO appointment is expected to take effect on or before December 15. Cunningham, who most recently served as president and CEO of Quanterix, will also join the company’s board of directors. Stueland will remain as an adviser through January 31, 2027.
Key Takeaways
- GeneDx appointed Everett Cunningham as its next CEO and a member of its board of directors
- Cunningham is expected to assume the position on or before December 15, 2026
- Katherine Stueland will leave the CEO position and board when Cunningham begins his role
- Stueland will remain as executive adviser through January 31, 2027
- Cunningham brings more than 35 years of experience across healthcare, diagnostics and pharmaceuticals
- GeneDx President Mark Gardner will remain in his position and report to Cunningham
GeneDx Appoints Everett Cunningham as Its Next CEO
GeneDx announced on November 18 that its board of directors had selected Everett Cunningham to succeed Katherine Stueland as chief executive officer. The appointment is scheduled to take effect no later than December 15, 2026.
Cunningham will also become a Class II director on the company’s board. His board term is scheduled to expire at GeneDx’s 2029 annual stockholders’ meeting.
Before accepting the appointment, Cunningham served as president and CEO of Quanterix, a company specializing in precision biomarker science. He held that position from January through November 2026.
GeneDx Chairman Keith Meister identified Cunningham’s experience in commercial healthcare leadership as an important consideration in the board’s decision. His background includes managing diagnostics businesses and expanding the commercial operations of established healthcare companies.
The appointment places Cunningham in charge of GeneDx, a genomics company that provides exome and genome sequencing services used in diagnosing rare genetic diseases.
GeneDx also confirmed that President Mark Gardner will retain his position and report directly to Cunningham following the leadership change.
Cunningham Brings More Than 35 Years of Healthcare Experience
Everett Cunningham has spent more than 35 years working across diagnostics, genomics, medical technology and pharmaceutical businesses.
Before joining Quanterix, he served as chief commercial officer of Illumina from June 2024 to January 2026. His responsibilities included overseeing the company’s global commercial strategy and execution.
Cunningham previously held the chief commercial officer position at Exact Sciences from 2021 to 2024, where he managed marketing, sales and customer service across the company’s cancer screening and precision oncology portfolio.
His earlier executive positions included president and CEO of GE Healthcare’s U.S. and Canada region from 2019 to 2021 and senior vice president of commercial operations at Quest Diagnostics from 2012 to 2019.
Other healthcare organizations have also selected executives with extensive industry experience for senior leadership positions. The American Hospital Association’s CEO selection in 2026 named Steve Walsh, who previously led the Massachusetts Health & Hospital Association, to succeed longtime chief executive Rick Pollack.
Cunningham’s career also includes more than two decades at Pfizer, where he held leadership positions involving pharmaceutical sales and regional operations. His appointments included regional president for established products in Asia Pacific and vice president of U.S. pharmaceutical sales.
He currently serves on the board of Arvinas and holds a bachelor’s degree in economics from Northwestern University.
Katherine Stueland to Leave After Five-and-a-Half Years
Katherine Stueland will step down as GeneDx chief executive and resign from the company’s board when Cunningham assumes his position.
Stueland joined GeneDx approximately five and a half years before the November 2026 announcement. Her tenure included the company’s combination with Sema4, business expansion and efforts to improve its financial performance.
GeneDx Chairman Keith Meister credited Stueland with leading the company’s transformation and expanding its rare disease diagnostics operations.
The leadership change includes a defined advisory period. Stueland will remain employed as executive adviser, reporting to the board, through January 31, 2027. Her continued involvement will support the transfer of responsibilities to Cunningham.
A similar arrangement involving continuing responsibilities for an outgoing executive appears in Stryker’s planned CEO succession. Stryker’s Kevin Lobo is scheduled to become executive chair when Spencer Stiles takes over as CEO in January 2027. GeneDx’s arrangement differs because Stueland will serve in a temporary advisory capacity rather than a continuing board leadership position.
GeneDx’s November 18 regulatory filing also stated that Stueland’s departure was not related to a disagreement concerning the company’s operations, policies or practices.
The advisory agreement establishes January 31, 2027, as the scheduled end of her employment with GeneDx.
GeneDx Establishes December Leadership Transition Timeline
The board approved Cunningham’s appointment on November 15, 2026, with the company publicly announcing the decision three days later.
The transition has two principal dates. Cunningham is expected to become chief executive on or before December 15, while Stueland’s advisory period is scheduled to continue through January 31, 2027.
When Cunningham assumes the CEO position, he will also join the board. Stueland’s resignation from her board seat will take effect on the same date.
GeneDx’s regulatory filing outlines Cunningham’s compensation arrangements, including an initial annual base salary of $750,000 and a target annual cash bonus equal to 100% of his base salary beginning in fiscal 2027. His agreement also includes a sign-on bonus and equity awards subject to specified conditions.
The compensation package includes restricted stock units linked to continued service and performance-based awards tied to stock price targets.
These arrangements establish the financial terms of Cunningham’s appointment alongside the planned transfer of executive and board responsibilities.
Mark Gardner Retains GeneDx President Role
GeneDx President Mark Gardner will remain in his position after Cunningham becomes chief executive.
Gardner was appointed president in June 2026, taking responsibility for the company’s laboratory and commercial operations. His appointment followed senior leadership experience at Quest Diagnostics and other healthcare businesses.
Under the new leadership structure, Gardner will report directly to Cunningham while continuing to oversee his existing responsibilities.
Cunningham has identified expanding the adoption of exome and genome sequencing as a priority for GeneDx. His previous experience managing commercial operations at diagnostics companies is relevant to that objective.
GeneDx also reaffirmed its full-year 2026 financial guidance in connection with the November 18 leadership announcement. The guidance had previously been provided on November 9 alongside the company’s third-quarter financial results.
The company did not announce additional changes to its president position or broader executive reporting structure as part of Cunningham’s appointment.
Frequently Asked Questions
Why is Katherine Stueland leaving GeneDx?
GeneDx announced Stueland’s departure as part of its executive leadership transition. Its regulatory filing stated that her departure was not related to disagreements over company operations, policies or practices.
How long has Katherine Stueland served as GeneDx CEO?
Stueland has served as GeneDx CEO for approximately five and a half years. Her tenure included the company’s combination with Sema4 and expansion of its genomics diagnostics business.
Will Katherine Stueland remain involved after stepping down?
Yes. Stueland will remain employed as executive adviser through January 31, 2027, reporting to the company’s board during the transition.
Who is GeneDx President Mark Gardner?
Mark Gardner became GeneDx president in June 2026. He oversees laboratory and commercial operations and will report to Everett Cunningham after the CEO transition.
What was Everett Cunningham’s previous CEO position?
Cunningham served as president and CEO of Quanterix from January through November 2026. Before that, he held senior commercial leadership positions at several healthcare and diagnostics companies.






